SCHEMBL13833663

SCHEMBL13833663

CC(=O)Nc1sc2c(c1-c1nc3ccccc3s1)CCCC2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 12/20 0.74
USP2 O75604 2/20 0.68
ATM Q13315 1/20 0.68
UHRF1 Q96T88 4/20 0.68
POLB P06746 2/20 0.67
KDM4E B2RXH2 2/20 0.67
MEN1 O00255 2/20 0.67
HTT P42858 2/20 0.67
KMT2A Q03164 2/20 0.67
NPC1 O15118 1/20 0.67
RECQL P46063 1/20 0.67
RAB9A P51151 1/20 0.67
BLM P54132 1/20 0.67
MAPT P10636 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
ALDH1A1 P00352 1/20 0.57
TP53 P04637 1/20 0.57
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13833863 0.87 APEX1 (0.89) APEX1USP2ATMUHRF1POLB
SCHEMBL13833598 0.87 APEX1 (0.90) APEX1USP2ATMUHRF1POLB
SCHEMBL13735540 0.86 APEX1 (0.70) APEX1USP2ATMUHRF1POLB
SCHEMBL18295789 0.86 MYC (0.74) APEX1MYC
SCHEMBL20248801 0.86 APEX1 (0.56) APEX1USP2ATMUHRF1POLB
SCHEMBL20248810 0.86 APEX1 (0.56) APEX1USP2ATMUHRF1POLB
SCHEMBL13833601 0.85 APEX1 (0.74) APEX1USP2ATMUHRF1POLB
SCHEMBL13735474 0.85 APEX1 (1.00) APEX1USP2ATMUHRF1POLB
SCHEMBL13832368 0.85 APEX1 (0.70) APEX1USP2ATMUHRF1POLB
SCHEMBL13735620 0.85 APEX1 (0.68) APEX1USP2ATMUHRF1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. 2013-03-21 US disclosed
WO-2012154888-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS PROTEOSTASIS THERAPEUTICS, INC. (US) 2012-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072473-A1 COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS HSPA5, PSMG3, VCP APEX1 2669/4885USP2 1350/4885ATM 3637/4885
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1196/4885USP2 4320/4885ATM 1594/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 APEX1 1879/4885USP2 4506/4885ATM 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.